Amikacin

Amikacin (BAY 41-6551) is a semisynthetic kanamycin analog that is active against most Gram-negative bacteria, including gentamicin- and tobramycin-resistant strains. Significant inhibitory effect. Amikacin is ototoxic and nephrotoxic. Amikacin can be used in bacteriostatic, anti-cancer and analgesic studies[1][2][3][4][5].

Product Specifications

CAS Number

[37517-28-5]

Product Name Alternative

BAY 41-6551

UNSPSC

12352005

Hazard Statement

H317

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/amikacin.html

Purity

99.93

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@H]([C@@H](C[C@H](N)[C@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)O)([H])O[C@@H]2CN)NC([C@@H](O)CCN)=O)O[C@@]([C@@H]([C@@H](N)[C@@H]3O)O)([H])O[C@@H]3CO

Molecular Formula

C22H43N5O13

Molecular Weight

585.60

Precautions

H317

References & Citations

[1]Farhan SM, et al. In Vitro and In Vivo Effect of Amikacin and Imipenem Combinations against Multidrug-Resistant E. coli. Trop Med Infect Dis. 2022 Oct 2;7 (10) :281. |[2]Wang YH, et al. Amikacin Suppresses Human Breast Cancer Cell MDA-MB-231 Migration and Invasion. Toxics. 2020 Nov 20;8 (4) :108. |[3]Atamer-Simsek S, et al. Antinociceptive effect of amikacin and its interaction with morphine and naloxone. Pharmacol Res. 2000 Mar;41 (3) :355-60. |[4]Ladrech S, et al. Calpain activity in the amikacin-damaged rat cochlea. J Comp Neurol. 2004 Sep 13;477 (2) :149-60. |[5]Chan K, et al. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00859-20.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Aminoglycoside

Citation 01

ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|AMB Express. 2024 Dec 24;14 (1) :141.|Antimicrob Agents Chemother. 2024 Oct 29:e0094524.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Authorea. 2025 Sep 17.|bioRxiv. 2025 May 30.|Commun Biol. 2025 Oct 6;8 (1) :1425.|EBioMedicine. 2025 May 30:117:105776.|Eur J Clin Microbiol Infect Dis. 2025 Jun;44 (6) :1493-1500.|Eur J Clin Microbiol Infect Dis. 2025 Sep 29.|Int J Antimicrob Agents. 2025 Jun 9:107551.|Int J Med Microbiol. 2023 Mar 28;313 (2) :151578.|J Antimicrob Chemother. 2020 Sep 1;75 (9) :2609-2615.|J Clin Microbiol. 2025 Aug 20:e0084125.|Microbiol Spectr. 2025 May 19:e0307424.|Pathogens. 2025 Mar 21;14 (4) :302.|ACS Chem Biol. 2022 Jan 21;17 (1) :39-53.|bioRxiv. 2024 May 10.|Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|Appl Microbiol Biotechnol. 2022 Apr;106 (7) :2689-2702.|Curr Microbiol. 2021 Dec 14;79 (1) :12.|J Antimicrob Chemother. 2020 Jul 1;75 (7) :1850-1858.